Utility of genomic testing in children, adolescents, and young adults with cancer
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djae233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Emily Debortoli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute, The University of Queensland, Dermatology Research Centre, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Neoplasms, Genetic Testing, Genomics, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Australian Government Research Training, Australian Government Research Training Program Scholarship, National Health and Medical Research Council.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Genomic testing can inform the diagnosis and personalize management of cancers in children, adolescents, and young adults (CAYA). This scoping review explored the clinical utility and impact of genomic testing in general CAYA cancer cohorts. Relevant records published in English between 2017 and 2024 were identified by searching PubMed. 36 studies (32 original articles; 4 reviews) were identified on genomic testing in CAYA cancers, most of which were advanced cancers. Studies internationally reported that approximately 16%-18% of CAYAs with cancer carry an associated pathogenic germline variant where 40% are de novo, and can guide treatment (eg, DNA repair gene variants). Somatic variants, predominantly copy number or structural rearrangements, inform diagnosis in up to 95% of primary cancers. Between 18% and 69% of patients have a somatic variant with a matched therapy, but only one third receive the genomic-guided recommendation, predominantly due to declining patient condition. Few studies evaluated the impact of matched therapies on response and survival. Combining comprehensive DNA and RNA sequencing maximises sensitivity. Circulating tumour DNA was detected in most primary cancers and shows high concordance with tumour tissue. In conclusion, genomic testing of CAYA cancers is feasible, informs diagnoses and guides personalised care. Further research is needed on response to genomic-guided treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Frazer Institute, The University of Queensland, Dermatology Research Centre, Brisbane, QLD, Australia.
- School of Clinical Medicine, University of New South Wales Sydney, Sydney, NSW, Australia.
- Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia.
- Children's Cancer Institute, University of New South Wales Sydney, Sydney, NSW, Australia.
- Cancer Australia, Sydney, NSW, Australia.
- Caring Futures Institute, Flinders University, Adelaide, SA, Australia.
ORCID-Profile: Emily Debortoli, Tatiane Yanes, Noemi Fuentes-Bolanos, Aideen McInerney-Leo
Förderung
- Australian Government Research Training
- Australian Government Research Training Program Scholarship
- National Health and Medical Research Council
- University of Queensland Faculty of Medicine
- Cancer Institute NSW Career Development Fellowship
Zitieren
APA
Debortoli, E., McGahan, E., Yanes, T., Berkman, J., Fuentes-Bolanos, N., Milch, V., Steinberg, J., & McInerney-Leo, A. (2025). Utility of genomic testing in children, adolescents, and young adults with cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae233
Vancouver
Debortoli E, McGahan E, Yanes T, Berkman J, Fuentes-Bolanos N, Milch V, et al. Utility of genomic testing in children, adolescents, and young adults with cancer. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae233
BibTeX
@article{Debortoli2025,
author = {Debortoli, Emily and McGahan, Ella and Yanes, Tatiane and Berkman, Jennifer and Fuentes-Bolanos, Noemi and Milch, Vivienne and Steinberg, Julia and McInerney-Leo, Aideen},
title = {Utility of genomic testing in children, adolescents, and young adults with cancer},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djae233}
}
EUVIMED